-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $3

Benzinga·12/11/2025 12:57:02
語音播報
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $3.